Mayo Clinic investigators have published research findings concluding that a drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases. The study was posted on Gastroenterology, the online journal of the American Gastroenterological Association.
Portal hypertension is a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. It is associated with cirrhosis and other chronic liver diseases. Mayo investigators have found that sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The Mayo researchers derived the results from preclinical experiments from mouse models. They have also been confirmed in human liver samples, according to lead author Vijay Shaah, MD.
Sivelestat is an inhibitor of human neutrophil elastase. It is used in the treatment of acute respiratory failure and preliminary studies show it may also improve neuropathic pain. It is owned by Japan-based Ono Pharmaceuticals. The Mayo research among other things is uncovering that Neutrophils are drivers of portal hypertension. Lead Research/Investigator
Vijay Shaah, MD
Moira Hilscher, M.D